Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given an average recommendation of “Hold” by the eleven ratings firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.1250.

Several research analysts recently commented on NMRA shares. Mizuho set a $6.00 target price on shares of Neumora Therapeutics in a research note on Monday, January 5th. Leerink Partners started coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus boosted their price target on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a report on Monday, November 17th. Finally, Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $4.00 to $7.00 in a report on Monday, December 1st.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $3.20 on Tuesday. The company has a market capitalization of $534.68 million, a P/E ratio of -2.18 and a beta of 3.20. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a 50 day moving average price of $2.40 and a two-hundred day moving average price of $2.16.

Insider Buying and Selling

In related news, insider Paul L. Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the sale, the insider owned 7,395,185 shares in the company, valued at $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 23,387 shares of company stock valued at $82,647 over the last ninety days. Company insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NMRA. Virtu Financial LLC boosted its stake in shares of Neumora Therapeutics by 465.7% during the 4th quarter. Virtu Financial LLC now owns 97,408 shares of the company’s stock valued at $174,000 after purchasing an additional 80,189 shares in the last quarter. Invesco Ltd. raised its stake in Neumora Therapeutics by 23.8% in the fourth quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock worth $407,000 after buying an additional 43,795 shares in the last quarter. XTX Topco Ltd purchased a new stake in Neumora Therapeutics in the fourth quarter worth about $204,000. Ikarian Capital LLC boosted its position in Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after acquiring an additional 1,265,910 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC grew its holdings in shares of Neumora Therapeutics by 74.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 72,106 shares of the company’s stock worth $129,000 after acquiring an additional 30,866 shares during the period. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.